I. The long-term fate of an oral dose of ['sSe]selenite was studied in three young women. 2. Urinary and faecal excretion, respiratory and dermal losses and whole-body retention of W e were measured, and also 75Se turnover in whole body, blood and tissues during a period of 16-20 weeks.
Urine samples were collected in plastic bottles and the volume made up to 1.7 1 with deionized water before radioactivity was measured in a large volume counter together with a 75Se reference standard.
The large volume counter was constructed in the Department of Medical Physics, Wakari Hospital, Dunedin. Radioactivity in the urine samples or reference standard was determined while the container was rotated at 0-1 Hz between two uncollimated 50 mm diameter sodium iodide scintillation crystals connected in series through a pulse height analyser to an I.D.L. scaler and timer (Series No. 7000). The counting efficiency of this system is approximately 1-2 yo. Tests have shown that the counting rate recorded from a 76Se source in this system is not dependent upon the volume of distribution of the source or its shape or position within the counting system, provided that the whole source is contained within the space occupied by the 1-7 1 container.
Stable Se in each 24 h urine collection was determined fluorimetrically (Watkinson, 1966) . Urinary excretion of radioactivity after the 2nd week was calculated as: specific activity of the weekly urine sample x mean daily excretion of stable Se for the same subject determined from the samples obtained during the first 14 d.
Collection of faeces
A gelatin capsule containing 50 mg brilliant blue marker (FD & C No. I, Bates Chemical Division, Crompton & Knowles Corporation, Landsdowne, Pa) and zoo mg methyl cellulose (Kempthorne & Prosser, Dunedin, New Zealand) was swallowed immediately after the 75Se dose. All individual stools passed by subjects G, W and R until day 45, day 14 and day 20 respectively, were collected separately. Thereafter a single faecal sample was obtained each week on the day of the urine collection.
Faeces were collected in weighed, waxed-cardboard containers. Radioactivity was measured in the large volume counter and the faeces were then dried to constant weight (6o0-So0), ground to a fine powder and the stable Se content determined fluorimetrically (Watkinson, 1966) . Faecal loss of 75Se after the 2nd week was calculated by the method used for urinary excretion.
Collection of blood samples
Blood samples (10-15 ml) were collected in heparinized tubes from each subject at hourly intervals for 10 h after administration of the dose. Samples were then taken daily for the first week, on days 10 and 14 and then weekly for 19 weeks.
Plasma and erythrocytes were separated by centrifugation and the cells washed with normal saline. Radioactivity in 2 ml portions of plasma and erythrocytes was measured in an automatic sample counter (Autogamma, Nuclear Chicago Corporation) with a T3e standard.
Measurement of respiratory excretion Expired air from each subject was collected in Douglas bags for 8-10 min periods at regular intervals during the first 9 h after administration of the 75Se dose and also from subject R for one period of 10 min on day z. Radioactivity in each filled bag was measured by the method used for whole-body counting (see below). The bag was then VOl. 32 Metabolism of [75Se] selenite in young women 49 emptied by bubbling the air serially through two bottles containing saturated mercuric chloride solution and a third bottle containing concentrated HNO,. Radioactivity in these bottles was measured in the large volume counter.
Measurement of dermal loss Two methods were used: ( a ) absorption of dermal losses in cotton underwear, long underpants and T-shirts, worn continuously for 2 d by subject G (days I and 2) and subject W (days 2 and 3) and (6) collection of 'arm-bag sweat' in pIastic bags enclosing the hand and arm up to the axilla worn by subjects G and R for periods of 30-50 min at intervals on day I. Radioactivity in clothing and plastic bags was measured in the large volume counter.
Whole-body counting
Whole-body radioactivity was measured for 200 s with the subject seated 1.8 m from an uncollimated NaI crystal, 120 mm in diameter. The crystal was linked to an automatic scaler-timer with pulse height analyser (Radiax, Deltronic Nuclear, Delft, Holland). The efficiency of this whole-body counting system was approximately 0-1 %. Radioactivity was measured immediately after ingestion of the dose, at hourly intervals for 9-1 I h, daily for I week, on days 10 and 14 and then once each week for 14-19 weeks.
Measurement of organ radioactivity
An estimate of radioactivity in the liver, heart, knee (chosen to represent bone) and thigh (subject G) or calf muscle (subjects W and R) was made using the 120 mm NaI crystal with a flat field collimator, the face of which was applied to the body. On day I the position of maximum counts over each organ was marked on the body to ensure identical positioning for the subsequent measurements. When counting over the liver or heart the collimator was directed in such a way as not to accept gamma-rays originating from the region of the kidney. These measurements were made each day for I week, on days 10 and 14 and thereafter weekly for 14-19 weeks.
RESULTS

Urinary excretion of 75Se
75Se was excreted rapidly in urine during day I, and the peak excretion rates of 0-4-1.4 % 75Se dose/h occurred within 2 h. The excretion rate then decreased to less than 0.1 % dose/h at 12 h.
Urinary losses on day I were 6.1, 4.2 and 2.8% dose for subjects G, W and R, respectively. By day 2 they had decreased to 1.7, 0.7 and 0.6 yo doseid and by the end of the 2nd week were 0.2-0.4% dose/d. Total urinary excretion in these 14 d was Urinary excretion (mean 2 SD) of stabIe Se was 16-7 2 1-8, 8-5 k 1-0 and 1 2 . 7~ 1.7 pg/24 h respectively for subjects G, W and R.
Faecal loss and intestinal absorption of 75Se
The cumulative loss of 75Se in faeces is illustrated in Fig. I . Faecal radioactivity and the coloured marker both appeared together on day 2 or 3 and peak excretion of 75Se occurred on day 4 or 5. The marker persisted in faeces until radioactivity in individual samples had decreased to less than I % of the dose on day 6 or 7.
Intestinal absorption of 75Se was estimated by plotting cumulative faecal excretion of 75Se during the first 2-3 weeks against time (Lutwak, 1969) . The straight line joining the last points on the curve was extrapolated back to the time of first appearance of brilliant blue faecal marker (day 2 for subjects W and R and day 3 for subject G).
This zero point on the extrapolated line represents the fraction of tracer not absorbed (Fig. I) . By this method it was calculated that 70, 64 and 4 % dose was absorbed by subjects G, W and R, respectively ( Table I) .
Cumulative faecal excretion at day 14 was 33, 40 and 58 yo dose for subjects G, W Mean faecal stable Se during the initial collection period was 9.7, 9.8 and 10.2 ,ug/ 24 h for subjects G, W and R, respectively.
Respiratory and dermal losses of 75Se
Measurements with the whole-body counter indicated that there was no radioactivity in the Douglas bags containing expired air. However on day I , traces of 75Se of less than 0.02% of the dose were found in the HNO, and mercuric chloride solutions through which expired air had been passed, but there was no 75Se in the air collected on day 2.
No radioactivity was detected in 'arm-bag sweat' or in cotton underwear worn during the first 2 or 3 d.
Whole-body retention and turnover of 75Se Total body retention of 75Se was estimated direct from whole-body radioactivity measurements and indirect from estimates of urinary and faecal losses.
Whole-body radioactivity measurements during day I varied from hour to hour by as much as 15 yo of the dose. This may have resulted from changes in the distribution of radioactivity in the body. For example the whole-body counts of subjects G and W increased considerably after a meal, possibly because of increased blood flow to the digestive organs or the effect of peristalsis upon intestinal 75Se. Small changes of body position in the chair used for the measurement had no effect on counting rates. Body retention of 75Se is illustrated in Fig. 2 . At the end of the 2nd week, values for retention of 75Se estimated by whole-body counting were less than those calculated from urinary and faecal excretion by 7% of the dose for both subjects G and W (Table I) . After this period the curves for body retention w. time for each method of estimation were parallel. The retention curves for subject R showed no consistent pattern in the first 6 d but after this period the values obtained by the two methods were similar. Values for total body retention of 75Se, estimated from measured urinary and faecal losses, were 60, 56, and 38 % of the dose at day 7 and 53, 5 1 and 35 at day 14 for subjects G, W and R, respectively. Values for the retention of absorbed tracer for the three subjects were 82,87 and 84% at day 7 and 76,80 and 82 yo at day 14 respectively.
The whole-body retention curves could each be resolved into three exponential components. The first two of these described an initial phase of rapid decrease corresponding with the elimination of unabsorbed faecal tracer and urinary excretion of absorbed but non-utilized '5Se. Half-times for retention obtained using whole-body counting measurements were 1.4, 0.8 and 0.8 d for phase I , and 14, 7 and 4 d for phase 2 in subjects G, W and R, respectively; corresponding values obtained using urinary and faecal excretion measurements were 0.8, 0.7 and 1-2 d and 7, I I and 8 d.
These two phases were followed by a more gradual decrease in radioactivity which also approximated to an exponential decline with half-times of 109, 143 and 92 d (from whole-body counting) or 109, 144 and 96 d (from measured excretion) for subjects G, W and R, respectively. 
Tissue retention and turnover of 75Se
Estimates of radioactivity in the liver, heart, knee and calf or thigh muscle were combined for the three subjects (Fig. 3) . 7SSe retention curves obtained for the liver and heart could be resolved into three exponential components (cf. whole-body curves). There was a more rapid decline of radioactivity in the liver than in the heart.
Half-times for phases I, 2 and 3 were 0.65, 6.7 and 73 d respectively for the liver, and 1.3, 15 and 89 d for the heart. Only small amounts of radioactivity were found in muscle and knee and these decreased during the first 5 d. After this period they remained relatively constant. 75Se turnover in plasma and erythrocytes 75Se concentrations in plasma during day I increased after the first hour to reach a peak at 7, 10 and 12 h for subjects G, W and R respectively. Only trace amounts of 75Se were found in erythrocytes on day I . Highest concentrations of 75Se were found in the plasma of subject G, while the lowest concentrations were found in subject R ; these values corresponded to the relative completeness of absorption of 75Se by these subjects.
Concentrations of 75Se in plasma and erythrocytes of subject R after day I are illustrated in Fig. 4 . The curves for plasma 75Se concentrations v. time for all three subjects were resolved into three exponential components with respective half-times of 0'7-1.4 d, 5.2-9.1 d and 69-77 d. 75Se concentrations in erythrocytes increased in the first z weeks to reach a plateau which was maintained for about 13 weeks. After this period erythrocyte 75Se concentration decreased.
D I S C U S S I O N
Intestinal absorption of [75Se]selenite
The validity of using this method for the measurement of intestinal absorption of 75Se selenite was established with rats by Thomson & Stewart (1973) . I n rats, absorption was also estimated by two other independent methods which utilized ( a ) the https://www.cambridge.org/core/terms. https://doi.org/10.1079/BJN19740057 Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 07 Dec 2018 at 21:03:46, subject to the Cambridge Core terms of use, available at difference in total faecal excretion of 75Se between rats given an oral dose of tracer and those given an intravenous dose, and (b) the ratio of whole-body radioactivities of the same two groups of rats 7 d after administration of the dose. If either of these methods were to be employed in human subjects it would be necessary to administer selenite orally and intravenously using two different radionuclides of Se. This was not possible as there is no other nuclide suitable for biological studies.
Absorption of [75Se] selenite varied considerably among the three subjects and it was considerably less than the mean absorption, 92% of the dose, in rats.
Respiratory excretion of 75Se As the capacity of the Douglas bag restricted a single collection of expired air to a period of 8-10 min, total respiratory loss of 75Se could not be estimated accurately. However, values obtained were less than 0'14% dose/h in the first 9 h and 75Se was not detected in expired air collected on day 2.
Other workers have shown that in animals there is a respiratory loss of Se as dimethyl selenide only during the first few hours after administration of an oral or intravenous dose of selenite or selenomethionine (Hirooka & Galambos, 1966 ; McConnell & Roth, 1966; Lopez, Preston & Pfander, 1969; Handreck & Godwin, 1970 ). Lathrop, Harper & Malkinson (1968) found that less than 2 % of an intravenous dose of [75Se] selenomethionine was eliminated in the breath of their two patients, mainly in the first few hours. No radioactivity was detected after 60 h. Thus respiratory loss of tracer doses of 75Se does not appear to be significant in man. Whole-body retention of 75Se Measurement of whole-body retention. There was a large difference in values for whole-body retention of 75Se obtained by whole-body counting and from combined urinary and faecal excretion in subjects G and W. It is unlikely that this difference was the result of underestimating losses by excretion, as respiratory and dermal losses of 75Se in the first few days when the discrepancy became apparent were negligible. The considerable variation in apparent whole-body radioactivity on day I suggested that this measurement was affected by a change in the distribution of the 75Se in the body. Furthermore, plots of whole-body retention v. time for the two methods were parallel from 4 to 7 d after administration of the dose; after this period regional distribution of 75Se in rats is fairly constant (Thomson & Stewart, 1973) .
Dermal losses of 76Se
Initial retention of 75Se. Retention of 75Se by the three human subjects given an oral dose of [75Se] selenite was less than that by rats because intestinal absorption was greater in rats (Thomson & Stewart, 1973) . However, retention of absorbed tracer was greater in the human subjects. Calculated values for the amount of absorbed [75Se] selenite retained by rats indicated that 73 and 62 yo was retained at 7 and 14 d, respectively. The lower retention in rats was associated with a greater urinary loss and may have resulted from the larger carrier doses of stable Se relative to body-weight given to the rats. It has been shown that the amount of 75Se retained by rats at the end of the initial period of rapid elimination is inversely related to the amount of carrier Se (Ewan, Pope & Baumann, 1967; Burk, Brown, Seely & Scaief, 1972) .
Tissue turnover of 75Se The turnover rates for the liver were the highest of the four tissues studied, particularly during the first few days, suggesting that this organ has a special role in the early metabolism of Se.
The similarity between the 75Se turnover curve for the heart and that for whole blood, and the higher concentrations of '%e in blood than in the heart muscle of rats (Thomson & Stewart, 1973) , suggested that it was the 75Se content of the cardiac blood pool which was estimated.
Turnover rates of 75Se in skeletal muscle and bone were lower than those of liver and blood, indicating relatively slow metabolism of Se in these tissues. The decrease in radioactivity of muscle and bone during the first few days might have resulted from a decrease in plasma 75Se content.
75Se turnover in plasma
The continuing increase in plasma 75Se content during the first 7-12 h was not the result of delayed absorption from the gastrointestinal tract. The maximum rate of excretion of radioactivity in urine occurred within 2 h of administration of the dose, indicating that absorption had been rapid. Awwad, Potchen, Adelstein & Dealy (1966) have suggested that after intravenous injection, 75Se is rapidly cleared from the blood by the liver and is then returned to the blood in a protein-bound form. This 'posthepatic' form of 75Se is not excreted in urine as readily as selenite, as the amount of 75Se in urine was decreasing during the period in which plasma radioactivity was increasing.
The initial rapid phases in the decrease of plasma 75Se content after day I could represent utilization of this 'post-hepatic' form of Se by the tissues or turnover of 75Se incorporated into other rapidly metabolized serum proteins. The final phase might represent long-term metabolism and re-utilization of 75Se incorporated into serum proteins with a slow turnover rate.
Whole-body turnover of 75Se
The initial phases of whole-body turnover were followed by a gradual disappearance of radioactivity which appeared to represent metabolic turnover and excretion in urine and faeces of 75Se which had become incorporated into a long-term Se pool.
There have been considerable differences in reported turnover rates of this Se pool in human subjects. Cavalieri, Scott & Sairenji (1966) found a mean biological halftime of 65 d after an intravenous dose of [75Se] selenite, and after intravenous doses of
